silevimig (GR1801) / Zhixiang (Shanghai) Pharma - LARVOL DELTA

Study to Evaluate GR1801's Efficacy and Safety (clinicaltrials.gov) - P3 | N=1200 | Completed | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion

Development of a novel bispecific antibody GR1801 for rabies. (PubMed, J Med Virol) - "In vivo, GR1801 provided protection equivalent to that of human RIG in golden hamsters challenged with lethal RABV. In conclusion, these findings demonstrate the neutralization potency and breadth of GR1801, which can be a promising candidate drug for rabies PEP, and a comprehensive testing against a broad spectrum of Chinese prevalent RABVs will be investigated in great detail in the future for the in vitro and in vivo studies."

Journal • Infectious Disease

Study to Evaluate GR1801's Efficacy and Safety (clinicaltrials.gov) - P3 | N=1200 | Recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.

New P3 trial